International Journal of Frontiers in Medicine, 2024, 6(8); doi: 10.25236/IJFM.2024.060808.
Wu Yingying, Hao Zhao
Department of Oncology, The Second Naval Hospital of the Southern Theater Command of PLA, Sanya, China
To develop a prognostic model for breast cancer based on the expression of ferroptosis-related proteins combined with clinical variables. Breast cancer data were downloaded from The Cancer Genome Atlas (TCGA) database for this study. The differentially expressed genes (DEGs) between tumor and normal tissues were intersected with ferroptosis-related genes. R language software was used to analyze and visualize the test cohort data to construct the prognostic model.The expressions of EMP1, TF, SLC7A5, and LMO1 were identified as independent risk factors for breast cancer. The predictive model, based on the expression levels of these four genes combined with clinical factors, showed strong predictive power for the survival status of breast cancer patients at 3, 4, and 5 years.
Breast Cancer, Ferroptosis, Predictive Model
Wu Yingying, Hao Zhao. Building a Prognostic Model for Breast Cancer Survival Based on Ferroptosis-Related Genes. International Journal of Frontiers in Medicine (2024), Vol. 6, Issue 8: 55-59. https://doi.org/10.25236/IJFM.2024.060808.
[1] Li YN, Xie B, Zhang Y, He MH, Xing Y, Mu DM, Wang H, Guo R. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023) World J Gastroenterol. 2023; 29:5593–5617.
[2] Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, Pu J, Lv J. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023; 29:2452–2468.
[3] Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell. 2012; 149:1060–1072. doi: 10.1016/j.cell.2012.03.042.
[4] Yagoda N., von Rechenberg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., Wolpaw A.J., Smukste I., Peltier J.M., Boniface J.J., et al. RAS–RAF–MEK-Dependent Oxidative Cell Death Involving Voltage-Dependent Anion Channels. Nature. 2007;447: 865–869. doi: 10.1038/nature05859.
[5] Chen X., Comish P.B., Tang D., Kang R. Characteristics and Biomarkers of Ferroptosis. Front. Cell Dev. Biol. 2021; 9:637162. doi: 10.3389/fcell.2021.637162.
[6] Yang W.S., Stockwell B.R. Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells. Chem. Biol. 2008; 15:234–245. doi: 10.1016/j.chembiol.2008.02.010.
[7] Hu D., Zhou Z., Wang J., Zhu K. Screening of Ferroptosis-Related Genes with Prognostic Effect in Colorectal Cancer by Bioinformatic Analysis. Front. Mol. Biosci. 2022;9:979854. doi: 10.3389/fmolb. 2022. 979854.
[8] Liu C., Liu Y., Yu Y., Zhao Y., Yu A. Comprehensive Analysis of Ferroptosis-Related Genes and Prognosis of Cutaneous Melanoma. BMC Med. Genom. 2022;15:39. doi: 10.1186/s 12920-022- 01194-z.
[9] Wang N., Gu Y., Li L., Chi J., Liu X., Xiong Y., Jiang S., Zhang W., Zhong C. Identification of Novel Prognostic Risk Signature of Breast Cancer Based on Ferroptosis-Related Genes. Sci. Rep. 2022; 12:13766. doi: 10.1038/s41598-022-18044-8.
[10] Lebert, J. M., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018). Advances in the systemic treatment of triple-negative breast cancer. Current oncology (Toronto, Ont.), 25(Suppl 1), S142–S150.
[11] Caulfield, S. E., Davis, C. C., & Byers, K. F. (2019). Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients with a BRCA1/2 Mutation. Journal of the advanced practitioner in oncology, 10(2), 167–174.
[12] Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation, 121(7), 2750–2767.
[13] Jiang, H., Li, M., Du, K., Ma, C., Cheng, Y., Wang, S., Nie, X., Fu, C., & He, Y. (2021). Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction. Chinese medicine, 16(1), 129.
[14] Robert, M., Patsouris, A., Frenel, J. S., Gourmelon, C., Augereau, P., & Campone, M. (2018). Emerging PARP inhibitors for treating breast cancer. Expert opinion on emerging drugs, 23(3), 211–221.
[15] Marcus, L., Donoghue, M., Aungst, S., Myers, C. E., Helms, W. S., Shen, G., Zhao, H., Stephens, O., Keegan, P., &Pazdur, R. (2021). FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, 27(4), 928–932.
[16] Zheng RS, Zhang SW, Sun KX, Chen R, Wang SM, Li L, Zeng HM, Wei WW, He J. [Cancer statistics in China, 2016]. Zhonghua Zhong Liu Za Zhi. 2023 Mar 23;45(3):212-220. Chinese. doi: 10.3760/cma.j.cn112152-20220922-00647. PMID: 36944542.
[17] Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024). Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal transduction and targeted therapy, 9(1), 55. https://doi.org/10.1038/s41392-024-01769-5
[18] Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585:113–8. doi: 10.1038/s41586- 020-2623-z.
[19] Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Res. 2019; 21:94. doi: 10.1186/s13058 -019-1177-1.
[20] Huang R, Wang H, Hong J, Wu J, Huang O, He J, Chen W, Li Y, Chen X, Shen K, Wang Z. Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. Front Immunol. 2023 Sep 4; 14: 1251643. doi: 10.3389/fimmu. 2023. 1251643.
[21] Zhu S, Zhang X, Weichert-Leahey N, Dong Z, Zhang C, Lopez G, Tao T, He S, Wood AC, Oldridge D, Ung CY, van Ree JH, Khan A, Salazar BM, Lummertz da Rocha E, Zimmerman MW, Guo F, Cao H, Hou X, Weroha SJ, Perez-Atayde AR, Neuberg DS, Meves A, McNiven MA, van Deursen JM, Li H, Maris JM, Look AT. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell. 2017 Sep 11;32(3):310-323.e5. doi: 10.1016/j.ccell.2017.08.002. Epub 2017 Aug 31.